Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimers disease

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 30, Issue 6, 2015, Pages 995-1001

  Mao, Fei ^a,b   Li, Jianheng ^a   Wei, Hui ^c   Huang, Ling ^a   Li, Xingshu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; cholinesterase inhibitor; hepatotoxicity; neurotoxicity

Indexed keywords

6 CHLORO N (PROP 2 YN 1 YL) 1,2,3,4 TETRAHYDROACRIDIN 9 AMINE; 6 CHLORO N DI(PROP 2 YN 1 YL) 1,2,3,4 TETRAHYDROACRIDIN 9 AMINE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; N (PROP 2 YN 1 YL) 1,2,3,4 TETRAHYDROACRIDIN 9 AMINE; N 1 (PROP 2 YN 1 YL) N 2 (1,2,3,4 TETRAHYDROACRIDIN 9 YL)ETHANE 1,2 DIAMINE; N 1 N 1 DI(PROP 2 YN 1 YL) N 2 (1,2,3,4 TETRAHYDROACRIDIN 9 YL)ETHANE 1,2 DIAMINE; NOOTROPIC AGENT; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG; PARGYLINE; PROPARGYLAMINE; PROPYLAMINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; LIVER TOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; STELLATE CELL; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATIC STELLATE CELLS; HUMANS; MOLECULAR STRUCTURE; PARGYLINE; PROPYLAMINES; STRUCTURE-ACTIVITY RELATIONSHIP; TACRINE;

EID: 84945944901     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2014.1003212     Document Type: Article

References (33)

1. Burns A, Iliffe S. Alzheimer's disease. BMJ 2009;338:467-71.
2. Iqbal K, del C. Alonso A, Chen S, et al. Tau pathology in Alzheimer disease and other tauopathies. BBA - Mol Basis Dis 2005;1739:198-210.
3. Praticò D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 2008;29:609-15.
4. Querfurth HW, LaFerla FM. Alzheimer's disease. New Engl J Med 2010;362:329-44.
5. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C. The cholinergic hypothesis: a historical overview, current perspective, and future directions. Ann NY Acad Sci 1985;444:332-58.
6. Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 1992;21:381-96.
7. Chianella C, Gragnaniello D, Maisano Delser P, et al. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 2011;67:1147-57.
8. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70.
9. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45.
10. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiat 2000;157:4-15.
11. Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053-65.
12. Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alz Dis Assoc Dis 2003;17:S105-13.
13. Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother 2011;11:1359-70.
14. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA - J Am Med Assoc 1994;271:992-8.
15. Marco-Contelles J, León R, de los Ríos C, et al. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2006;49:7607-10.
16. Fernandez-Bachiller MI, Perez C, Gonzalez-Munoz GC, et al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J Med Chem 2010;53:4927-37.
17. Fernandez-Bachiller MI, Perez C, Campillo NE, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. Chem Med Chem 2009;4:828-41.
18. Kochi A, Eckroat TJ, Green KD, et al. A novel hybrid of 6-chlorotacrine and metal-amyloid-β modulator for inhibition of acetylcholinesterase and metal-induced amyloid-β aggregation. Chem Sci 2013;4:4137-45.
19. Hamulakova S, Janovec L, Hrabinova M, et al. Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease. Eur J Med Chem 2012;55:23-31.
20. Chen X, Zenger K, Lupp A, et al. Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo. J Med Chem 2012;55:5231-42.
21. Chen Y, Sun J, Fang L, et al. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J Med Chem 2012;55:4309-21.
22. Mao F, Chen J, Zhou Q, et al. Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. Bioorg Med Chem Lett 2013;23:6737-42.
23. Youdim MBH, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001;939:450-8.
24. Yogev-Falach M, Amit T, Bar-Am O, Youdim MBH. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J 2003;17:2325-7.
25. Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 2005;19:1899-901.
26. Sagi Y, Mandel S, Amit T, Youdim MBH. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 2007;25:35-44.
27. Kupershmidt L, Amit T, Bar-Am O, et al. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice. Mol Neurobiol 2012;46:217-20.
28. Tang J, Li J, Zhang L, et al. The divergent transformations of aromatic o-aminonitrile with carbonyl compound. J Heterocyclic Chem 2012;49:533-42.
29. Mao F, Huang L, Luo Z, et al. O-hydroxyl- or o-amino benzylaminetacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation. Bioorgan Med Chem 2012;20:5884-92.
30. Ellman GL, Courtney KD, Andres V, Featherstone RM. Biochem Pharmacol 1961;7:88-95.
31. Bolognesi ML, Andrisano V, Bartolini M, et al. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. J Med Chem 2005;48:24-7.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
33. Schnabl B, Choi YH, Olsen JC, et al. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest 2002;82:323-33.